Healthcare sector emerges as defensive haven as tech momentum cools
With the Health Care Select Sector SPDR Fund trading below 18 times trailing earnings, investors are scrutinising subsegments ranging from pharmaceuticals to medical devices for opportunities amid macroeconomic volatility.
Amid rising macroeconomic volatility and a perceived cooling in technology sector momentum, the healthcare sector is emerging as a defensive investment destination. The Health Care Select Sector SPDR Fund (XLV), currently the sixth-largest sector in the S&P 500, is attracting contrarian interest due to its low beta of 0.58 and valuation metrics trading below 18 times trailing earnings. Analysts highlight a divergence within the sector, urging investors to scrutinise specific subsegments rather than relying on the broad index.
Technical indicators for XLV show a promising percentage price oscillator, although moving averages have not yet turned up meaningfully. The sector's performance is heavily concentrated: in 2026, just 10 holdings account for 60% of XLV’s assets, dominated by specific drug makers, healthcare providers, and medical device manufacturers. This concentration underscores the need for granular analysis beyond the monolithic safety trade label often applied to the fund.
Medical devices, represented by the iShares U.S. Medical Devices ETF (IHI), are facing compressed margins due to a "higher-for-longer" interest rate environment. The segment is heavily driven by procedure volumes and capital expenditure budgets at major hospitals. Despite recent underperformance, analysts suggest the segment may be sufficiently "washed out" to present a buying opportunity for those seeking operational leverage and tech-driven growth exposure.
Healthcare providers, such as UnitedHealth and Elevance Health, are characterised as cash-flow utilities. These companies are exposed to regulatory policy, corporate benefit trends, and government reimbursement rates. Their stable nature offers a different risk profile compared to the high-beta growth orientation of the medical device segment, providing a middle ground for investors seeking steady cash flows amidst regulatory uncertainty.
The pharmaceutical sub-sector, including Eli Lilly, Merck, and Pfizer, is insulated by patent portfolios and recurring global spend. Analysts note potential for artificial intelligence to augment drug discovery speed and increase profit margins. For investors seeking defensive insulation and reliable yield, the VanEck Pharmaceutical ETF (PPH) is suggested as a vehicle to capture the pricing power and robust fundamentals of legacy drug makers.
As technology market enthusiasm fades, the sector's historically low volatility may attract capital seeking stability. The healthcare sector provides a multitrillion-dollar cushion of inelastic demand, with people requiring medical treatment regardless of interest rate fluctuations or individual chipmaker earnings. This fundamental resilience, combined with current valuation discounts, positions the sector as a strategic counterweight to top-heavy equity markets.
Navigating healthcare requires understanding exactly which engine is driving capital allocation. Whether through the defensive insulation of pharmaceuticals or the growth potential of medical devices, the sector offers distinct pathways for portfolio protection. The coming period will likely see markets reassess the value of this low-beta asset class as macroeconomic conditions continue to evolve.
